Olaf Degen

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Characteristics of late HIV diagnosis in Germany in 2019 and 2020 - A regional analysis.

Characteristics of late HIV diagnosis in Germany in 2019 and 2020 - A regional analysis.

Journal: Infection

Published: July 03, 2026

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.

Efficacy of dolutegravir or bictegravir-containing therapy in a real-life cohort of people with HIV-1 sub-subtype A6.

Journal: AIDS (London, England)

Published: February 17, 2026

MPXV H3L elicits broadly directed CD4 T cell responses in mpox patients and MVA vaccinees.

MPXV H3L elicits broadly directed CD4 T cell responses in mpox patients and MVA vaccinees.

Journal: Npj viruses

Published: February 10, 2026

Five-Year German PrEP cohort reveals high HIV protection and persistent STI burden: implications for individualized and flexible prevention strategies.

Five-Year German PrEP cohort reveals high HIV protection and persistent STI burden: implications for individualized and flexible prevention strategies.

Journal: Infection

Published: July 13, 2025

Long-Term Real-World Use of Cabotegravir/Rilpivirine: Adherence and Virological Efficacy over a 44-Month Observation Period.

Long-Term Real-World Use of Cabotegravir/Rilpivirine: Adherence and Virological Efficacy over a 44-Month Observation Period.

Journal: Infectious diseases and therapy

Published: April 13, 2025

Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study.

Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study.

Journal: EClinicalMedicine

Published: February 28, 2025

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10).

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10).

Journal: Vaccines

Published: January 13, 2025

Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study.

Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: August 14, 2024

AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999-2018.

AIDS-defining events among people living with HIV who have been under continuous antiretroviral therapy for more than one year, a German cohort study 1999-2018.

Journal: Infection

Published: November 15, 2023

Geno2pheno: recombination detection for HIV-1 and HEV subtypes.

Geno2pheno: recombination detection for HIV-1 and HEV subtypes.

Journal: NAR molecular medicine

Published: November 02, 2023

Lack of evidence of acute HEV infections as a sexually transmitted disease: Data from a German cohort of PrEP users.

Lack of evidence of acute HEV infections as a sexually transmitted disease: Data from a German cohort of PrEP users.

Journal: The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

Published: August 31, 2023

Cooperation with the university ambulance

Cooperation with the university ambulance

Journal: MMW Fortschritte der Medizin

Published: May 30, 2023

Showing 1-12 of 53

Last Updated: 09/26/2026